Mr. Hillerstrom is a co-founder of NeuroPhage and serves as Executive Vice President and Chief Financial Officer. He spent 3 years as an associate at leading European biotech venture capital firm HealthCap where he participated in a large number of investment transactions including several IPOs. More recently Mr. Hillerstrom spearheaded a project at AstraZeneca to evaluate decision-making leading to Phase III clinical trials. Previously Mr. Hillerstrom was a partner in the Zurich-based consulting boutique Venture Valuation specialized in the assessment and valuation of biotech companies. For a year prior to that he worked in mergers and acquisitions at the investment bank Lazard in the pharmaceutical and chemicals industry teams. Mr. Hillerstrom holds a Masters in Economics and Finance from the University of St. Gallen, an MBA from Harvard Business School, and an MSc in Health Sciences and Technology from MIT/Harvard Medical School (HST).